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While anti-VEGF drugs are commonly used to inhibit pathological retinal and choroidal
neovascularization, not all patients respond in an optimal manner. Mechanisms
underpinning resistance to anti VEGF therapy include the upregulation of other
proangiogenic factors. Therefore, therapeutic strategies that simultaneously target multiple
growth factor signaling pathways would have significant value. Here, we show that
Ca2+/calmodulin-dependent kinase II (CAMKII) mediates the angiogenic actions of a range
of growth factors in human retinal endothelial cells and that this kinase acts as a key nodal
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Introduction
Aberrant angiogenesis is a pathological hallmark of  several diseases, including rheumatoid arthritis and 
solid tumor growth (1, 2). In the retina, pathological angiogenesis underlies some of  the major causes 
of  blindness in developed countries, such as retinopathy of  prematurity (ROP), proliferative diabetic 
retinopathy (PDR), and neovascular (wet) age‑related macular degeneration (nvAMD) (3). Increased 
levels of  VEGF are thought to play a key role in the development of  pathological angiogenesis in these 
conditions (4). Anti‑VEGF therapy has now become a mainstream treatment for nvAMD (5) and has 
been reported to have beneficial effects in other ocular angiogenic diseases (6, 7). However, despite the 
effectiveness of  anti‑VEGF therapy, many patients do not respond optimally to these drugs or they 
become refractory after prolonged treatment (8, 9). Resistance to anti‑VEGF therapy is perhaps most 
easily explained by the involvement of  other angiogenic mediators in driving the neovascular response, 
with previous work strongly implicating several other growth factors, including basic fibroblast growth 
factor (bFGF), insulin‑like growth factor‑1 (IGF‑1), and hepatocyte growth factor (HGF) in regulating 
pathological angiogenesis in the eye (3, 10–14). These observations suggest that the identification of  new 
therapeutic targets involved in orchestrating the complex proangiogenic effects of  multiple growth factors 
could lead to efficacious new approaches for major blinding diseases.
Ca2+/calmodulin‑dependent kinase II (CAMKII) is a serine/threonine protein kinase involved in 
translating intracellular Ca2+ signals into cellular responses (15). It consists of  4 different isoforms 
with distinct expression patterns, suggesting that isoform‑specific interventions might be relatively 
tissue selective. In vascular endothelial cells, both the γ and δ isoforms have been found to be strong‑
ly expressed at both the mRNA transcript and protein level (16). Presently, we have only a limited 
understanding of  the function of  CAMKII in vascular endothelial cells, although studies to date have 
While anti-VEGF drugs are commonly used to inhibit pathological retinal and choroidal 
neovascularization, not all patients respond in an optimal manner. Mechanisms underpinning 
resistance to anti-VEGF therapy include the upregulation of other proangiogenic factors. Therefore, 
therapeutic strategies that simultaneously target multiple growth factor signaling pathways would 
have significant value. Here, we show that Ca2+/calmodulin-dependent kinase II (CAMKII) mediates 
the angiogenic actions of a range of growth factors in human retinal endothelial cells and that this 
kinase acts as a key nodal point for the activation of several signal transduction cascades that are 
known to play a critical role in growth factor–induced angiogenesis. We also demonstrate that 
endothelial CAMKIIγ and -δ isoforms differentially regulate the angiogenic effects of different 
growth factors and that genetic deletion of these isoforms suppresses pathological retinal and 
choroidal neovascularization in vivo. Our studies suggest that CAMKII could provide a novel 
and efficacious target to inhibit multiple angiogenic signaling pathways for the treatment of 
vasoproliferative diseases of the eye. CAMKIIγ represents a particularly promising target, as 
deletion of this isoform inhibited pathological neovascularization, while enhancing reparative 
angiogenesis in the ischemic retina.
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revealed a role for this kinase in modulating ion homeostasis, nitric oxide production, and agonist‑in‑
duced changes in vascular permeability (17). We have previously reported that CAMKII acts as a key 
signaling molecule underlying VEGF‑induced angiogenic activity in retinal endothelial cells in vitro 
(18), but whether it is involved in angiogenic signaling mediated by a broader range of  growth factors 
remains unknown. Further validation of  CAMKII as a potential therapeutic target for ocular angio‑
genic disorders also requires a clearer understanding of  its contribution to retinal neovascularization in 
vivo, the downstream signaling pathways through which it mediates its proangiogenic effects, and the 
role of  specific endothelial CAMKII isoforms. The aim of  the current study was to address these issues 
using in vitro and in vivo models of  retinal angiogenesis combined with pharmacological, siRNA 
knockdown, and whole‑animal gene knockout approaches. Our data show that CAMKII is a potential 
target for the development of  improved antiangiogenic therapies for the eye and that targeting either 
CAMKIIγ or ‑δ isoforms provides a potentially novel approach for differentially modulating angiogen‑
ic signaling through different growth factors in the retina.
Results
CAMKII mediates the angiogenic actions of  a range of  growth factors in retinal endothelial cells. The wider con‑
tribution of  CAMKII to growth factor–induced retinal angiogenic signaling in vitro was evaluated with 
focus on the ability of  VEGF, bFGF, HGF, and IGF‑1 to activate CAMKII in human retinal microvas‑
cular endothelial cells (HRMECs). Time‑dependent effects on the phosphorylation level of  the CAMKII 
autoactivation site at T287 was assessed using Western blot analysis. Growth factor concentrations (25 
ng/ml) were chosen to fall within the range reported in the vitreous and retina of  patients with ocular 
neovascular disease (~5–50 ng/ml) (10, 19–21). VEGF, bFGF, HGF, and IGF‑1 increased the amount 
of  phosphorylated CAMKII, with peak levels differentially occurring between 1–3 hours after treatment 
(Figure 1A) and then dropping back toward basal levels within 24 hours. In contrast to these other growth 
factors, platelet‑derived growth factor (PDGF) had no effect on CAMKII phosphorylation, thereby act‑
ing as a negative control for these experiments (Supplemental Figure 1; supplemental material available 
online with this article; https://doi.org/10.1172/jci.insight.122442DS1).
To directly study the role of  CAMKII in eliciting angiogenic responses to VEGF, bFGF, HGF, and 
IGF‑1, we used a tubulogenesis assay, in which endothelial cells form capillary‑like tubes within a Matrigel 
matrix (22). All of  the growth factors tested stimulated tubulogenesis by ~3‑ to 4‑fold when compared with 
untreated control cells (Figure 1B; P < 0.001 for all growth factors vs. untreated controls). Treatment of  
HRMECs with the CAMKII inhibitor KN93 (10 μM), but not its inactive analogue KN92 (10μM), sup‑
pressed growth factor–induced tubulogenesis to levels that did not significantly differ from those of  untreat‑
ed control cells (Figure 1B; P > 0.05 for all growth factors plus KN93 vs. untreated controls). KN93 had no 
effects on tubulogenesis in control HRMECs in the absence of  added growth factors (Figure 1B; P > 0.05).
The effects of  CAMKII inhibition on growth factor–induced migration and proliferation in HRMECs 
were also assessed. VEGF, bFGF, HGF, and IGF‑1 increased HRMEC migration and proliferation (Figure 
2, A and B; P < 0.01 and P < 0.05 for all growth factors vs. untreated control cells for the 2 assays, respec‑
tively), and these effects were inhibited by KN93 but not KN92 (Figure 2, A and B; P > 0.05 for all growth 
factors plus KN93 vs. untreated controls in both assays). Consistent with our tubulogenesis findings, basal 
migration and proliferation were unaffected by KN93 in control HRMECs in the absence of  added growth 
factors (Figure 2, A and B; P > 0.05). To ensure that KN93 did not affect cell viability, we performed Trypan 
blue exclusion assays, and prolonged exposure (24 hours) of  HRMECs to this inhibitor had no effect on 
cell viability when compared with control and KN92‑treated cells (Figure 2C; P > 0.05). Taken together, 
the above experiments suggest that CAMKII activation represents a critical signaling step through which 
various growth factors initiate angiogenic activity in human retinal endothelial cells.
VEGF induces the phosphorylation of  several kinases in a CAMKII-dependent manner. We have pre‑
viously reported that VEGF‑induced phosphorylation of  the proangiogenic protein, Akt (S473), is 
dependent on CAMKII activation in retinal endothelial cells (18). To gain a more thorough under‑
standing of  the downstream signaling pathways through which CAMKII regulates angiogenic activ‑
ity, phospho‑kinase array experiments were conducted. HRMECs were exposed to VEGF (25 ng/
ml) for 24 hours in the absence or presence of  KN92 or KN93, and the phosphorylation levels of  
the individual kinases represented on the array were compared with untreated control cells. VEGF 
alone increased phosphorylation of  13 of  43 kinases included in the array (Supplemental Table 1). 
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KN93, but not KN92, blocked VEGF‑induced phosphorylation of  JNK, Akt (S473), Yes, Src, and 
FAK, suggesting that these kinases are activated in a CAMKII‑dependent manner (Figure 3). In sili‑
co analyses using 3 different site‑specific kinase‑substrate prediction algorithms (Scansite 4.0, iGPS, 
and PhosphoSitePlus; refs. 23–25) indicated that phosphorylation of  these proteins by CAMKII is 
likely to be indirect, suggesting the presence of  intermediate kinases in the signal transduction path‑
way. Using the array, β‑catenin protein expression was increased in HRMECs exposed to VEGF, 
which was largely reversed by KN93 but not KN92 (Figure 3 and Supplemental Table 1). VEGF had 
no effect on HSP60 protein levels (Supplemental Table 1).
Pharmacological inhibition of  CAMKII blocks retinal neovascularization in vivo. Thus far, our in vitro data 
supports the view that CAMKII may be a promising therapeutic target for the treatment of  ocular neo‑
vascular disorders. To test this possibility further, we explored the effects of  pharmacological inhibition of  
CAMKII on pathological retinal angiogenesis in vivo. The oxygen‑induced retinopathy (OIR) mouse mod‑
el was chosen for these studies because it is a well‑established model for studying pathological angiogenesis 
in the eye (26) and, similar to human ischemic retinopathies (e.g., ROP and PDR), neovascular pathology 
in this model involves multiple growth factors, including VEGF, bFGF, HGF, and IGF‑1 (27–30).
Figure 1. Ca2+/calmodulin-dependent kinase II (CAMKII) contributes to growth factor–induced retinal angiogenesis in vitro. (A) The time-dependent 
effects of various growth factors on the phosphorylation level of the CAMKII autoactivation site (T287) was investigated in human retinal microvascular 
endothelial cells (HRMECs) by Western blot analysis. Left, representative Western blots showing that VEGF, bFGF, HGF, and IGF-1 trigger CAMKII phos-
phorylation (pCAMKII) in HRMECs in a time-dependent manner. β-Actin was used as a loading control. Right, summary data calculated from the inte-
grated density of the protein bands (normalized to β-actin) and expressed as a fold-change from untreated cells (time 0). Data represent mean ± SEM; 
*P < 0.05, **P < 0.01, ***P < 0.001 vs. time 0 based on ANOVA; n = 4 biological replicates. (B) Tubulogenesis assays were performed on HRMECs that 
were untreated or treated with various growth factors in the absence or presence of the CAMKII inhibitor KN93 (10 μM) or its inactive analogue KN92 (10 
μM). Top, typical images showing the effects of KN93 and KN92 on VEGF-induced tube formation in HRMECs stained with calcein green. Scale bar: 100 
μm. Bottom, box-and-whisker plots (min, max, 25th–75th percentile, median) showing that VEGF, bFGF, HGF, and IGF-1 stimulate HRMEC tubulogenesis 
in a CAMKII-dependent manner. *P < 0.05, ***P < 0.001 based on ANOVA; n = 4 biological and 3 technical replicates.
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Following OIR induction, intravitreal injection of  mice at P15 with KN93 led to a significant reduc‑
tion in neovascularization at P17 when compared with OIR control animals (Figure 4, A and B). We also 
tested the effects of  a second structurally unrelated CAMKII inhibitor, CK59 (31). Like KN93, CK59 
suppressed neovascularization in the OIR model (Figure 4, A and B). Central avascular and normal 
vascular areas were also quantified for the various treatment groups and compared with OIR control 
animals. Avascular areas were greater in OIR mice intravitreally injected with KN93 or CK59, but there 
was no change in normal vascular area with these drugs (Figure 4, A and B). Neovascular, avascular, 
and normal vascular areas in mice intravitreally injected with KN92 were similar to those measured in 
OIR control animals (Figure 4, A and B). These data suggest that CAMKII signaling makes a significant 
contribution to ischemia‑induced neovascularization in the retina in vivo.
CAMKIIγ and -δ isoforms differentially regulate the angiogenic effects of  different growth factors. Our phar‑
macological data indicate that CAMKII is a key mediator of  growth factor–induced retinal angiogenesis 
in vitro and in vivo, but they provide no information on the identity of  the CAMKII isoforms involved. 
To address this issue, we employed an siRNA‑based approach to evaluate the effects of  knocking down 
expression of  specific CAMKII isoforms on growth factor–induced retinal angiogenesis in vitro. We 
Figure 2. Pharmacological inhibition of Ca2+/calmodulin-dependent kinase II (CAMKII) blocks growth factor–induced migration and proliferation of 
human retinal microvascular endothelial cells (HRMECs) with no effect on cell viability. (A) Left, representative phase-contrast images of the migra-
tion scratch wound assay showing the extent of wound repair following stimulation of HRMECs with VEGF in the absence or presence of the CAMKII 
inhibitor KN93 (10 μM) or its inactive compound KN92 (10 μM). Dashed and dotted lines indicate wound edges at time 0 and 18 hours, respectively. Scale 
bar: 100 μm. Right, box-and-whisker plots (min, max, 25th–75th percentile, median) showing that VEGF-, bFGF-, HGF-, and IGF-1–induced wound repair 
was inhibited by KN93 but not KN92. (B) BrdU-ELISA cell proliferation assay. Box-and-whisker plots show the median values of BrdU absorbance for 
each treatment condition. Preincubation of HRMECs with 10 μM KN93 reduced the increase in DNA synthesis induced by VEGF, bFGF, HGF, and IGF-1. (C) 
Prolonged (24-hour) exposure of HRMECs to 10 μM KN93 had no effect on cell viability as measured using the Trypan blue exclusion assay. *P < 0.05, 
**P < 0.01, ***P < 0.001 based on ANOVA; n = 4 biological and 3 technical replicates for each assay.
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focused these studies on CAMKIIγ and ‑δ, since these are known to be the primary isoforms expressed 
in endothelial cells (16) and since previous work has shown that expression of  CAMKIIα and ‑β in the 
retina is restricted to ganglion and amacrine cells (32, 33).
Knockdown of  CAMKIIγ expression in HRMECs inhibited tube formation induced by HGF and 
IGF‑1 when compared with cells transfected with nontargeting control siRNA (Figure 5A). In contrast, 
there were no significant changes in VEGF‑ and bFGF‑induced tubulogenesis in cells treated with CAM‑
KIIγ siRNA (Figure 5A). Knockdown of  CAMKIIδ resulted in a different pattern of  effects, suppressing 
tubulogenesis induced by VEGF, bFGF, and HGF, but not IGF‑1 (Figure 5A). The extent to which 
individual growth factors stimulated tubulogenesis did not differ significantly between nontransfected 
HRMECs and cells transfected with nontargeting control siRNA (P > 0.05 in all cases).
To investigate further a differential role for CAMKIIγ and ‑δ isoforms in mediating the angiogen‑
ic activity of  different growth factors, HRMEC migration and proliferation assays were performed. 
Results from these experiments were broadly consistent with the tubulogenesis assays, demonstrating a 
preferential involvement of  CAMKIIγ in IGF‑1– and CAMKIIδ in VEGF‑ and bFGF‑induced angio‑
genic signaling, with both isoforms making a significant contribution to HGF‑induced migration and 
proliferation (Figure 5, B and C). In these experiments, however, knockdown of  CAMKIIδ did have a 
small but significant effect on IGF‑1–induced migration (Figure 5B), and targeting CAMKIIγ reduced 
VEGF‑ and bFGF‑induced migration and proliferation, respectively (Figure 5, B and C). In control 
comparisons, growth factor–induced migration and proliferation were similar in untreated and nontar‑
geting control siRNA‑treated cells (P > 0.05 for all growth factors tested), and no effects on cell viabil‑
ity were observed in any of  the siRNA‑transfected groups (Figure 5D). Overall, these findings suggest 
that the angiogenic effects of  VEGF, bFGF, HGF, and IGF‑1 rely on the activation of  CAMKIIγ and 
‑δ isoforms to differing extents in vitro.
Genetic deletion of  CAMKIIγ and -δ isoforms reduces laser-induced choroidal neovascularization (CNV) in 
vivo. Building on our in vitro data, the role of  CAMKIIγ and ‑δ isoforms was evaluated in vivo using the 
laser‑induced mouse model of  CNV (34). In the neovascular form of  AMD, Bruch’s membrane damage 
is associated with the formation of  CNV lesions (3). Postmortem evaluation of  retinal flatmounts stained 
with isolectin B4 demonstrated a significant reduction in CNV lesion volumes in CAMKIIγ- and ‑δ–KO 
mice when compared with their WT counterparts (Figure 6).
Figure 3. Phospho-proteomic analysis of human retinal microvascular endothelial cells (HRMECs) using the R&D Systems Human Phospho-Kinase 
array. HRMECs were treated with VEGF in the presence or absence of the Ca2+/calmodulin-dependent kinase II inhibitor KN93 (10 μM) or its inactive 
compound KN92 (10 μM) and the phosphorylation level of individual kinases represented on the array compared with untreated (control) cells. (A) 
Representative images showing a selected region of the phospho-kinase array for control cells and HRMECs exposed to VEGF with or without KN93 or 
KN92 treatment. Each kinase is spotted in duplicate and the location of JNK, Akt (S473), Yes, Src, FAK, and β-catenin is denoted using colored boxes. 
(B) Quantitative analysis of the spots was performed by densitometry and presented as fold change vs. control cells. Data represent mean ± SEM. *P < 
0.05, **P < 0.01, ***P < 0.001 based on ANOVA; n = 2 biological replicates and 4 technical replicates per group.
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CAMKIIγ- and -δ–KO mice respond differently to ischemic retinopathy in vivo. The OIR model was used to 
further substantiate a role for CAMKIIγ and ‑δ isoforms in pathological retinal angiogenesis in vivo. CAM‑
KIIγ- and ‑δ–KO mice and their WT controls displayed a similar sensitivity to hyperoxic vasoregression, with 
no significant differences observed in avascular or normal vascular areas at P12 (Figure 7). After 5 days of  
ischemic hypoxia (P17), the degree of OIR in CAMKIIγ and ‑δ WT mice (Figure 7) was comparable with 
control animals in our previous pharmacological studies (avascular, neovascular, and normal vascular areas 
of 40%, ~20% and ~40%, respectively). When compared with their respective WT controls, CAMKIIγ- and 
‑δ–KO mice exhibited a substantial decrease in retinal neovascularization (Figure 7). A marked difference, 
however, was noted with regard to changes in the avascular and normal vascular areas between the 2 groups 
of KO animals. In CAMKIIγ KOs, avascular areas were similar, but normal vascular areas were significantly 
increased when compared with their WT littermates (Figure 7, A and C). In CAMKIIδ KOs, avascular areas 
were increased and normal vascular areas reduced in comparison with their WT controls (Figure 7, B and 
D). In separate studies, adult CAMKIIγ- and ‑δ–KO mice displayed no overt changes in the architecture of  
the retinal vascular network (Supplemental Figure 2) or in the gross morphology of the retina (Supplemental 
Figure 3) when compared with their WT littermate controls. These OIR data show that deletion of CAMKIIγ 
and ‑δ isoforms elicit different outcomes during ischemic retinopathy in vivo. Genetic ablation of CAMKIIγ 
inhibits preretinal neovascularization, while concomitantly enhancing vascular recovery within the ischemic 
tissue. Deletion of CAMKIIδ suppresses preretinal neovascularization, but also has a detrimental impact on 
reparative angiogenesis in the retina during the hypoxic phase of the OIR model.
Figure 4. Pharmacological blockade of Ca2+/calmodulin-dependent kinase II (CAMKII) suppresses pathological angiogenesis in the ischemic retina. 
The murine oxygen-induced retinopathy (OIR) model was used to explore the role of CAMKII in retinal neovascularization in vivo. (A) Top panels, typical 
images of P17 flat-mounted retinas following OIR in a control (no drug) animal and mice intravitreally injected at P15 with KN92 (negative control for 
KN93), KN93, and CK59 (CAMKII inhibitors). Lectin staining (green) identifies the retinal vasculature. Red (solid) and yellow (dashed) lines demarcate 
total retinal areas and avascular areas, respectively, as defined using OIR Select software. Scale bar: 1.0 mm. Lower panels, higher-magnification images 
of selected areas of the flatmount preparations highlighting the differences in neovascular tuft formation among the treatment groups. Scale bar: 
200 μm. (B) Box-and-whisker plots (min, max, 25th–75th percentile, median) of the neovascular, avascular, and normal vascular areas for the different 
groups expressed as a percentage of the total retinal area. *P < 0.05, ***P < 0.001 based on ANOVA; n = 10 mice per group.
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To investigate whether the differential effects of  knocking out CAMKIIγ and ‑δ during OIR might 
relate to differences in the normal cellular localization and expression of  these isoforms in the retina, we 
performed dual RNAscope in situ hybridization assays on retinal sections from P15 C57BL/6 control 
(normoxic) and OIR mice. Sections were colabeled with RNAscope probes for either CAMKIIγ (Camk2g) 
or CAMKIIδ (Camk2d) together with claudin‑5 (Cldn5) to positively identify the vascular endothelium. In 
control retinas, Camk2g and Camk2d exhibited similar distribution patterns, being localized not only to the 
vascular endothelium, but also to cells within the ganglion cell layer (GCL), inner nuclear layer (INL), and 
outer nuclear layer (ONL) (Supplemental Figure 4). Camk2d, but not Camk2g, mRNA expression was found 
to be significantly upregulated during OIR (Supplemental Figure 4). However, no obvious changes in the 
cellular localization of  these CAMKII isoforms were observed (Supplemental Figure 4).
Discussion
Anti‑VEGF drugs have revolutionized the management of patients with nvAMD, and they have shown great 
promise for the treatment of other ocular angiogenic diseases (35). Unfortunately, blockade of VEGF is not 
universally effective, and a significant subset of patients fail to respond or become refractory to treatment. 
Figure 5. Ca2+/calmodulin-dependent kinase II (CAMKII) γ and -δ isoforms differentially regulate the angiogenic effects of different growth factors. (A) 
VEGF-, bFGF-, HGF-, and IGF-1–induced tubulogenesis in human retinal microvascular endothelial cells (HRMECs) transfected with nontargeting, CAMK2G, 
or CAMK2D siRNAs. (B) Quantitative evaluation of the effects of CAMK2G and CAMK2D silencing on growth factor–induced HRMEC migration determined 
using the scratch-wound assay. (C) BrdU-ELISA results showing the effects of CAMK2G and CAMK2D knockdown on VEGF-, bFGF-, HGF-, and IGF-1–induced 
cell proliferation. (D) Percentage cell viability data measured using the Trypan blue method for HRMECs transfected with nontargeting, CAMK2G, or CAM-
K2D siRNAs. Data represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 based on ANOVA; n = 3 biological and 3 technical replicates for each assay.
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Pathological angiogenesis in the eye involves the concerted actions of multiple growth factors, and more effec‑
tive antiangiogenic therapies may need to go beyond targeting VEGF alone (36–38). Herein, we have identi‑
fied CAMKII as a common signaling step that is evoked by multiple proangiogenic growth factors, irrespec‑
tive of whether the pathological response was preretinal or subretinal. Our data suggest that this kinase could 
represent an important target for the development of improved antiangiogenic therapies for the eye.
The current study has demonstrated that CAMKII is activated in HRMECs by various growth fac‑
tors implicated in vasoproliferative diseases of  the eye and that its pharmacological inhibition prevents 
angiogenic responses induced by bFGF, HGF, and IGF‑1, as well as VEGF. Direct activation of  CAM‑
KII occurs upon an initial increase in intracellular Ca2+ and Ca2+/calmodulin binding (15), and most 
growth factors that signal through receptor tyrosine kinases are known to raise intracellular Ca2+ via 
the phospholipase Cγ/IP3/Ca
2+ signaling pathway (39). Indeed, a number of  studies have shown that 
VEGF, bFGF, HGF, and IGF‑1 can trigger Ca2+ mobilization from IP3‑sensitive Ca
2+ stores and Ca2+ 
entry across the plasma membrane in retinal and other types of  vascular endothelial cells (18, 40, 41). 
We have previously reported that VEGF‑induced retinal angiogenesis in vitro is prevented by treatment 
with the CAMKII inhibitor, KN93 (18), and the present study extends this work by showing that other 
important growth factors converge on CAMKII to mediate their angiogenic activity. Previous studies 
have demonstrated a requirement for CAMKII in growth factor–induced vascular smooth muscle cell 
(SMC) migration and proliferation (42, 43), while it may also regulate cancer cell proliferation, motil‑
ity, and metastasis (44). The exact mechanisms through which CAMKII modulates cell migration and 
proliferation have yet to be fully explored, although recent work has suggested that CAMKII‑dependent 
activation of  the Akt, MAPK, and CREB pathways may be involved (45–47).
In an effort to better understand the downstream signaling molecules through which CAMKII 
regulates angiogenic activity in HRMECs, we used a phospho‑kinase antibody array to identify kinases 
that are differentially phosphorylated by VEGF in the absence or presence of  the CAMKII inhibitor 
KN93. Several kinases were phosphorylated by VEGF in a CAMKII‑dependent manner, including 
JNK, Akt, Yes, Src, and FAK. These have all previously been shown to contribute to retinal angiogenic 
Figure 6. Laser-induced choroidal neovascularization (CNV) is reduced in CAMKIIγ- and -δ–KO mice. CNV lesions were generated using laser photoco-
agulation and quantified by multiphoton imaging of isolectin B4–stained retinal-choroidal flatmounts. (A and B) Representative 3-D images of isolectin 
B4–stained CNV lesions from CAMKIIγ and -δ WT and homozygous KO mice. Large CNV lesions are clearly evident within laser burns of the WT mice. 
Scale bars: 10 µm. (C and D) Box-and-whisker plots (min, max, 25th–75th percentile, median) comparing CNV lesion volumes (expressed as a percentage 
of the total burn volume) between CAMKIIγ and -δ WT and KO mice. KO animals exhibited significantly less CNV than their WT counterparts. **P < 0.01 
and ***P < 0.001 based on 2-tailed Student t test; n = 5–10 animals per group.
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responses in vitro and pathological neovascularization in the retina in vivo (48–52). Based on our in 
silico analyses, these proteins do not appear to be direct substrates of  CAMKII’s catalytic activity, sug‑
gesting that intermediate kinases are most likely responsible for their phosphorylation in response to 
CAMKII activation. Phosphorylation of  JNK, Akt, and FAK downstream to CAMKII activation has 
been reported previously (18, 53, 54), but we are unaware of  any earlier studies showing that CAMKII 
activity is required for growth factor–induced phosphorylation of  the Src family kinases Yes and Src. 
KN92, the kinase‑inactive control for KN93, had no effect on VEGF‑induced phosphorylation of  
JNK, Akt, Yes, Src, and FAK. In addition, a recent screen of  KN93 against a broad range of  human 
protein kinases has shown that this drug does not directly affect the activity of  any of  these kinases 
(55). Thus, it seems unlikely that the results from our phospho‑kinase arrays can be explained on the 
basis of  any nonspecific actions of  the KN93 compound. Our array studies also revealed a CAM‑
KII‑dependent increase in β‑catenin protein levels in HRMECs treated with VEGF. CAMKII‑depen‑
dent upregulation of  β‑catenin protein expression has been reported in other cell types (56), and this 
protein has been shown to promote endothelial cell angiogenic activity by regulating the expression of  
the cell cycle protein cyclin E2 (57). Overall, our phospho‑kinase array studies suggest that CAMKII 
stimulates angiogenic activity by acting as a key nodal point for the activation of  several signal trans‑
duction cascades that play a critical role in regulating growth factor–induced angiogenesis.
Figure 7. Oxygen-induced retinopathy (OIR) in CAMKIIγ- and -δ–KO mice. Pups were exposed to hyperoxia (75% O
2
) from P7–P12, followed by 5 days in 
room air to induce vascular insufficiency and preretinal neovascularization. Some mice were euthanized at P12 to assess the degree of retinal vascular 
regression. (A and B) Left and middle, isolectin B4–stained flat-mounted retinas from CAMKIIγ and -δ WT and homozygous KO OIR mice at P12 and P17. 
Red (solid) and yellow (dashed) lines demarcate total retinal areas and avascular areas, respectively. Scale bars: 1.0 mm. Right, magnified regions of the 
P17 retinal flatmounts. Scale bars: 200 μm. (C and D) Box-and-whisker plots (min, max, 25th–75th percentile, median) of avascular, neovascular, and 
normal vascular areas expressed as a percentage of the total retinal area for the various cohorts of mice at P12 and P17. Neovascularization was absent 
at P12 and, therefore, has not been plotted. *P < 0.05, **P < 0.01, ***P < 0.001 based on ANOVA (avascular and normal vascular) and 2-tailed Student t 
test (neovascular). Data is derived from a minimum of 10 mice per group.
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Up to now, an important question that has remained unanswered is whether CAMKII contributes to 
pathological angiogenesis in vivo. We have demonstrated that 2 structurally distinct CAMKII inhibitors, 
KN93 and CK59, suppress ischemia‑induced neovascularization in the OIR model. Furthermore, these drugs 
were found to block neovascularization without exerting any obvious effects on the preexisting vessels of  
the retina. It should be noted, however, that KN93 and CK59 are not isoform selective (31, 58), and from a 
therapeutic perspective, widespread blockade of all CAMKII isoforms in the retina would be expected to have 
a detrimental impact on retinal function. A splice variant of CAMKIIα, for example, has been implicated 
in mediating neuroprotection in retinal ganglion cells following glutamate excitotoxicity (59). Targeting of  
CAMKII for the treatment of retinal neovascular disease is, therefore, likely to require an isoform‑specific 
approach. As an important step toward this goal, we determined the contribution of individual endothelial 
CAMKII isoforms (γ and δ) to retinal angiogenesis in vitro and in vivo using molecular genetic strategies.
Our siRNA‑based studies revealed that both CAMKIIγ and ‑δ are involved in growth factor–induced 
retinal angiogenesis in vitro, although they appear to be linked to distinct signaling pathways. CAMKIIγ 
was required for IGF‑1– and CAMKIIδ was required for VEGF‑ and bFGF‑induced angiogenesis, with 
both isoforms contributing to the angiogenic effects of  HGF. To the best of  our knowledge, this is the first 
study to show that different growth factors can exert their actions by signaling through distinct CAMKII 
isoforms. Our data provide a basis for more detailed studies investigating the mechanisms through which 
different growth factors activate specific CAMKII isoforms in vascular endothelium.
The reductions in growth of  laser‑induced CNV lesions in CAMKIIγ- and ‑δ–KO mice represent 
key findings of  this study since this murine model is widely used to reproduce key aspects of  nvAMD 
(60). Genetic ablation of  both isoforms equally reduced CNV, whereas genetic ablation of  CAMKIIγ 
and ‑δ isoforms elicited differing effects in OIR (widely used model of  ROP), although both contribut‑
ed to pathological angiogenesis. Specifically, in the OIR model, physiological revascularization of  the 
ischemic tissue was enhanced in CAMKIIγ- but inhibited in CAMKIIδ‑KO mice. Our results in mice 
lacking CAMKIIγ, which siRNA studies showed was coupled with IGF‑1 signaling in HRMECs, bear 
strong resemblance to those previously reported in OIR mice with endothelial cell–specific deletion 
of  the IGF‑1 receptor (61). Similarly, KO of  CAMKIIδ, which was associated with bFGF signaling 
in HRMECs, produced effects in the OIR model comparable with those previously described in mice 
with targeted deletion of  endothelial cell FGF receptor signaling (28). To date, there have been no 
studies examining the consequences of  endothelial cell–specific deletion of  VEGF and HGF signaling 
in the OIR model. Since we used global KOs of  CAMKIIγ and ‑δ isoforms, we cannot completely rule 
out the possibility that the differential effects of  knocking out these isoforms on revascularization of  
the OIR retina may have resulted from changes at the level of  the retinal neurons and glial cells. Reti‑
nal neurons, for instance, have been shown to play an important role in modulating regenerative angio‑
genesis in the OIR model (62). In the present study, we have shown that, in addition to being localized 
to the vascular endothelium, CAMKIIγ and ‑δ are also expressed in the nonvascular cells of  the retina 
with distribution patterns that are similar in both normally perfused and ischemic retina. These obser‑
vations would suggest that the reasons why genetic ablation of  CAMKIIγ and ‑δ exert different effects 
in the OIR model cannot be simply explained on the basis of  differences in the localization patterns of  
these isoforms. Interestingly, we did find that the expression levels of  the 2 isoforms respond different‑
ly to ischemia (Camk2d mRNA was upregulated, while CamK2g remained unchanged). Nevertheless, 
these results are difficult to reconcile with the opposing effects of  these isoforms on reparative angio‑
genesis in the ischemic retina. Future work directed toward identifying the main substrates of  CAM‑
KIIγ and ‑δ in the nonvascular cells of  the retina may provide a useful starting point in attempting to 
unravel why deletion of  these 2 isoforms exerts different OIR responses.
In summary, this study demonstrates the critical role of  CAMKII in retinal angiogenesis. Our data 
support the idea that targeting of  either CAMKIIγ or ‑δ isoforms in the retina could provide a means of  
inhibiting the effects of  multiple angiogenic factors, offering potential advantages over current anti‑VEGF 
approaches. We have shown that both isoforms are potential therapeutic targets for the treatment of  CNV. 
For ischemic retinopathies, CAMKIIγ appears to be the most promising therapeutic target, as deletion 
of  this isoform inhibited neovascular growth while enhancing revascularization of  the ischemic retina. In 
contrast, genetic ablation of  CAMKIIδ not only suppressed pathological retinal neovascularization, but 
also had a detrimental effect on reparative angiogenesis. Since CAMKIIγ appears to mediate angiogenesis 
independently of  VEGF, targeting of  this isoform could potentially improve clinical outcomes when used 
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in combination with current anti‑VEGF therapies and provide an alternative treatment for patients who fail 
to respond or become refractory to these drugs. CAMKIIγ and ‑δ have been identified as important targets 
for the treatment of  a number of  cardiovascular diseases (17, 63, 64), and our work strengthens the ratio‑
nale for the development of  selective inhibitors against these isoforms for selected retinopathies.
Methods
Drugs and solutions. Recombinant VEGF165, bFGF, HGF, IGF‑1, and PDGF were obtained from R&D Sys‑
tems. The CAMKII inhibitor KN93 and its inactive analogue KN92 were purchased from Santa Cruz Bio‑
technology Inc. CK59 was obtained from Calbiochem. Stock solutions of  growth factors were prepared in 
PBS, while pharmacological agents were dissolved in DMSO. The DMSO concentration in the assays never 
exceeded 0.1% (vol/vol), a concentration that was found not to influence the results of  any of  the assays.
Cell culture. Primary HRMECs were purchased from Cell Systems and grown on 1% gelatin‑coated 
culture dishes in Cell Systems Corporation (CSC) complete medium (Cell Systems; 4ZO‑500) containing 
50 mg/ml primocin (InvivoGen). Cells were incubated at 37°C in a humidified atmosphere containing 
5% CO2 and used at passages 6–8. Unless otherwise stated, experiments were repeated a minimum of  4 
times using different batches of  HRMECs, with 3 technical replicates per batch of  cells.
Immunofluoresence. The endothelial characteristics of HRMECs were confirmed by immunolabeling stud‑
ies. Cells were seeded onto zero thickness glass coverslips (Scientific Laboratory Supplies) and fixed in 4% 
paraformaldehyde (PFA) at room temperature for 20 minutes prior to incubating in blocking and permea‑
bilization buffer (PB; 1% donkey serum and 0.05% Triton‑X 100 in PBS) for 1 hour at room temperature. 
HRMECs were then washed in PBS for 1 hour prior to incubation with the following primary antibodies over‑
night at 4ºC: β‑catenin (1:50; Santa Cruz Biotechnology Inc., catalog No Sc‑7963), CD31 (1:50; Santa Cruz 
Biotechnology Inc., catalog No Sc‑8306), vimentin (1:50; Dako, Agilent technologies, catalog M0725), von 
Willebrand factor (vWF; 1:50; Abcam, catalog Ab75117), CD105 (1:50; Dako catalog M3527), CD14 (1:50; 
Santa Cruz Biotechnology Inc., catalog Sc‑6999) and α‑smooth muscle actin (1:50; α‑SMA; Dako, cataog 
M0851). Cells were then washed and incubated with appropriate secondary antibodies (1:500 donkey anti‑
mouse [A21202] or anti‑rabbit Alexa Fluor488 [A21206]; Invitrogen) for 1 hour at room temperature. After 
washing, HRMECs were mounted onto Surgipath microscope slides (Leica Biosystems) with Vectashield 
containing the nuclear stain DAPI (Vector Laboratories Inc.). Images were captured using a Nikon Eclipse 
Ti‑U inverted C1 confocal microscope. HRMECs were positive for the endothelial cell markers vWF, CD31 
(PECAM‑1), CD105 (endoglin), β‑catenin, and vimentin (Supplemental Figure 5). In contrast, they were 
negative for markers of α‑SMA and macrophages (CD14) (Supplemental Figure 5).
Western blot analysis. Cells were lysed in RIPA buffer supplemented with a protease inhibitor cocktail 
(Halt Protease Inhibitor Cocktail, EDTA‑Free; 100×; 87785; Thermo Fisher Scientific). Supernatants 
were cleared by centrifugation at 16,000 g for 10 minutes (4°C), and protein concentration were deter‑
mined using a BCA protein assay kit (Thermo Fisher Scientific). Protein samples (30 μg) were separated 
on 10% SDS‑PAGE gels, transferred to PVDF membranes, and probed with polyclonal rabbit antibodies 
raised against phospho‑CAMKII (T287; 1:500; Abcam, catalog Ab138392) and mouse monoclonal anti–
β‑actin antibodies (1:10,000; Cell Signaling Technology, catalog 8H10D10, #3700). After washing, mem‑
branes were incubated with appropriate goat secondary antibodies (1:20,000) against rabbit or mouse 
IgG (IRDye 680 and IRDye 800; Li‑COR). Immunoreactive bands were detected using a Li‑COR Odys‑
sey system. All western blot data shown are representative of  at least 3 separate individual experiments.
Tubulogenesis assay. In this assay, endothelial cells form capillary‑like tubes within a Matrigel matrix (22). 
HRMECs (1 × 105 cells) were resuspended in CSC complete media containing 50% growth factor–reduced 
Matrigel (BD Biosciences) and 50 μl aliquots spotted onto 24‑well plates. After polymerization, spots were 
covered in CSC complete media containing test substances and incubated at 37°C for 24 hours. Cells were 
then labeled with Cell Trace Calcein Green AM (0.5 μg/ml for 30 minutes; Invitrogen), and endothelial tube–
like structures were imaged using fluorescence microscopy (Nikon Eclipse TS100). Tubulogenesis was quan‑
tified by measuring the tube area in 5 randomly selected low‑power fields (magnification ×10) from each well 
using NIS Elements software (Nikon), and data were presented relative to untreated control cells.
Scratch wound migration assay. HRMECs were grown to 80% confluence in CSC complete medium on 
1% gelatin‑coated 6‑well plates. A single uniform scratch wound that crossed each well was then performed 
using a sterilized 200 μl pipette tip. Following injury, cells were washed, and media containing test com‑
pounds were added. Scratch wound regions were imaged 0 and 18 hours after wounding using a phase 
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contrast microscope equipped with a digital camera (Nikon Eclipse TS100; E5400 camera; Nikon). Wound 
repair was calculated by subtracting the total wound area at 18 hours from the total wound area at 0 hours 
using ImageJ (NIH) software (65), and the data were normalized to untreated control cells. All scratch 
wound assays were performed in the presence of  5‑fluorouracil (1 mM) to prevent cell proliferation.
Proliferation assay. HRMECs were seeded at a density of  1 × 104 cells/well in 96‑well plates and cultured 
for 24 hours in CSC complete media. Media was then replaced with fresh CSC media containing test sub‑
stances, and the cells were incubated for a further 24 hours. BrdU was then added and its incorporation into 
HRMEC DNA measured using a colorimetric cell proliferation ELISA assay (Roche Diagnostics).
Cell viability. HRMECs were grown to 80% confluency in CSC complete media on 1% gelatin‑coat‑
ed 24‑well plates and treated with test substances for 24 hours. Cells were then collected by trypsiniza‑
tion, washed in PBS, and stained with 0.2% Trypan blue. The proportion of  viable cells was deter‑
mined from hemocytometer counts.
Phospho-kinase arrays. Phospho‑antibody array analysis was carried out using the Proteome Pro‑
filer Human Phospho‑Kinase Array (R&D Systems) according to the manufacturer’s instructions. 
HRMECs were cultured in 1% gelatin–coated T75 flasks in CSC complete media and exposed to test 
substances for 24 hours. Cells were lysed with Lysis Buffer 6 (R&D Systems) and agitated for 1 hour 
at 4°C. Cell lysates were clarified by microcentifugation at 14,000 g for 5 minutes, and protein concen‑
tration were determined using a BCA protein assay kit (Thermo Fisher Scientific). Array membranes 
were blocked with Array Buffer 1 (R&D Systems) and incubated overnight at 4°C with 600 μg of  cell 
lysate. The membranes were washed to remove unbound proteins and then incubated with biotinylat‑
ed detection antibodies and streptavidin‑HRP. Chemiluminescent detection reagents were applied to 
detect spot densities. Array images were analyzed using ImageJ software (65). Array spots were back‑
ground subtracted and normalized to positive control spots on each membrane to enable comparisons 
across the different treatment groups. The integrated density of  duplicated spots representing each 
phospho‑kinase protein was determined, and data were presented as the fold change compared with 
the untreated control group. The phospho‑antibody array experiment was repeated twice, comprising 
2 biological and 4 technical replicates per treatment group.
siRNA transfections. HRMECs were transfected with Dharmacon ON‑TARGETplus SMARTpool 
siRNAs specifically targeting human CAMK2G (catalog L‑004536‑00) or CAMK2D (catalog L‑004042‑00) 
isoforms for 24 hours using DharmaFECT reagent (Thermo Fisher Scientific). Dharmacon ON‑TAR‑
GETplus siCONTROL Nontargeting siRNA (catalog D‑001810‑10) was used as control siRNA. Quan‑
titative PCR (qPCR) was performed to determine knockdown efficiency as previously described (66). 
Primers (Integrated DNA Technologies) were designed to amplify human CAMK2G (forward primer 
5′‑TCCTGTATATCCTCCTGGT‑3′, reverse primer 5′‑CATCTGGTTGATCAAGTTC‑3′) and human 
CAMK2D (forward primer 5′‑GGATCTGTCAACGTTCTACT‑3′, reverse primer 5′‑TGTGGATTA‑
CAGTAGTTTGG‑3′), which were quantified relative to GAPDH (human, forward primer 5′‑GAGT‑
CAACGGATTTGGTCGT‑3′, reverse primer 5′‑GACAAGCTTCCCGTTCTCAG‑3′). Cells were 
transfected with 25 nM siRNA, a concentration that was found to consistently produce ≥80% transcript 
knockdown for each CAMKII isoform and where knockdown of  CAMK2G had no effect on CAMK2D 
mRNA expression and vice versa (Supplemental Figure 6).
Animals. For pharmacological experiments, C57BL/6 mice were purchased from Harlan Laborato‑
ries. CAMKIIγ‑KO (67) and CAMKIIδ‑KO (68) mice were provided by Prof  Eric Olson (University of  
Texas Southwestern Medical Center, Dallas, Texas, USA) and Johannes Backs (University of  Heidel‑
berg, Heidelberg, Germany). Heterozygous mice (+/–) were bred to produce CAMKIIγ and CAMKIIδ 
homozygous KO (–/–) and WT (+/+) mice. Mice were housed in standard microisolator cages in the Bio‑
logical Services Unit at Queen’s University of  Belfast and provided food and water ad libitum. Numbers 
of  mice used for each experiment are indicated in the figure legends.
Genotyping of  CAMKIIγ- and CAMKIIδ-KO mice. Genomic DNA was extracted from ear biopsies and 
amplified with the REDExtract‑N‑Amp Tissue PCR Kit (MilliporeSigma) using Camk2g and Camk2d prim‑
er mixes (Eurofin Genomics) before being loaded on to 1.5% agarose gel. The Camk2g primer mix (5′‑CAC 
TAG TGC ACA AAG CCT TTT CAA‑3′, 5′‑ACT TGG GGA GTT GGT TCT CTT TTC‑3′ and 5′‑TAC 
ACG GTA AAT GCC TCA CAT ACG‑3′) amplified a 207 bp WT band and 413 bp homozygous KO 
band. The Camk2d primer mix (5′‑GAG AAG GGC GAA GAC GTG ACA G‑3′, 5′‑GAT GAG AGA 
CCA CTC GAA GCT C‑3′ and 5′‑GCC AAA GGA CAT ATC ACA CTG G‑3′) amplified a 282 bp WT 
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band and 600 bp homozygous KO band. A representative genotyping gel image of  DNA from ear biopsies 
of  CAMKIIγ and CAMKIIδ WT and homozygous KO mice is shown in Supplemental Figure 7A.
Reverse transcription PCR (RT-PCR) amplification. Total RNA was extracted from flash‑frozen pairs of  
retinas from CAMKIIγ and CAMKIIδ WT and homozygous KO mice using a Qiagen RNeasy Mini 
Kit. Total RNA was quantified using a NanoDrop One spectrophotometer (Thermo Fisher Scientific), 
and cDNA was synthesized from 1 ng of  total RNA using a High Capacity cDNA Reverse Transcrip‑
tion kit (Thermo Fisher Scientific) primed with a mixture of  random primers. The cDNA RT products 
were amplified with Camk2g‑, Camk2d‑, and Actn1-specific (Actinin‑1–specific) primers using a REDEx‑
tract‑N‑Amp PCR ReadyMix kit (MilliporeSigma). Primer sequences were as follows: Camk2g, forward 
primer, 5′‑ACGACTACCAGCTTTTCGAGG‑3′, and reverse primer, 5′‑TTTGCAGCATATTCCTGC 
GT‑3′; Camk2d, forward primer, 5′‑CGGTTCACCGACGAGTATCA‑3′, and reverse primer, 5′‑TGG‑
CAGCATACTCTTGTCCAG‑3′; and Actn1, forward primer, 5′‑TGCCTCAT CAGCTTGGGTTA‑3′, 
and reverse primer, 5′‑AAGTCGATGAAGGCCTG GAA‑3′. PCR amplified products were resolved on 
2.5% agarose gels and visualized using Midori Green nucleic acid stain. RT‑PCR experiments confirmed 
retinal KO of  Camk2g and Camk2d in the respective KO mouse strains (Supplemental Figure 7B).
OIR model. Ischemic retinopathy was induced in C57BL/6, WT, and gene‑KO mice according to the 
protocol of  Smith et al. (69). Briefly, P7 mice and their nursing mothers were exposed to 75% oxygen 
(OxyCycler; Biospherix Ltd.) for 5 days to induce vasodegeneration and atrophy of  the central retinal 
capillary beds. At P12, mice were removed from the oxygen chamber and returned to normal room air 
to induce vascular insufficiency and ischemia‑driven neovascularization, a response that reaches a max‑
imum around P17 (70). To visualize the degree of  retinal vascular regression in the different groups of  
animals, some mice were euthanized at P12 and their eyes enucleated. This was important for studies 
using gene‑KO mice to ensure that any changes observed between groups at P17 could not be attributed 
to differences in the initial levels of  retinal ischemia produced at P12. For CAMKII inhibitor studies, 
mice were intravitreally injected with test substances (1 μl) at P15 using a 34‑G bevelled needle (Nanofil; 
World Precision Instruments) under general anaesthesia (60 mg/kg ketamine + 6 mg/kg xylazine, i.p.). 
P15 was chosen for the intravitreal injections since preretinal neovascularization in the OIR model begins 
around this time point (71). Reported drug concentrations represent the estimated end vitreal concentra‑
tions, calculated assuming a vitreal volume of  ~5 μl for a P15 mouse eye (72). One eye per mouse was 
treated with the contralateral untreated eye serving as an internal control. At P17, animals treated with 
CAMKII inhibitors, controls, WT, and gene‑KO mice were sacrificed, and their eyes were collected for 
quantification of  retinal neovascular, ischemic, and normally vascularized areas.
Preparation and quantitative assessment of  retinal flatmounts from OIR animals. Enucleated eyes were 
immersion fixed in 4% PFA for 2 hours and washed extensively. Retinas were isolated and the vascu‑
lature fluorescently stained with biotin‑labeled isolectin B4 (1:50; MilliporeSigma) and Alexa Fluor 
Streptavidin 488 (1:500; Invitrogen). Retinas were then flat‑mounted and imaged using a fluorescence 
microscope (Nikon Eclipse TS100). Neovascular, avascular and normal vascular areas were quantified 
as a percentage of  the total retinal area using OIR Select software developed within our laboratory. This 
ImageJ‑based plugin semiautomates the analysis of  OIR images using 4 user‑defined thresholding values 
based on Huang (73) (whole retina) and Otsu (74) (neovascular, avascular, and normal vascular areas) 
thresholding methods. Quantification of  normal vascular area has not been widely reported in OIR stud‑
ies, to date. The OIR Select software calculates the normal vascular area by subtracting the neovascular 
area from the total vascular area and expressing this as a percentage of  the total retinal area. This end‑
point provides an indication of  the degree of  physiological revascularization across the entire retina 
during OIR. The OIR Select software and detailed user guide is available in the Supplemental Data 2.
RNAscope in situ hydridization and image analysis. Manual RNAscope 2.5 HD Duplex assays were 
performed on formalin‑fixed paraffin‑embedded sections (5‑μm thickness) from P15 control (normoxic) 
and OIR mouse retinas according to the manufacturer’s protocols (ACDBio; Doc #322452‑USM and 
#322500‑USM). The following sets of  RNAscope probes were used in this study: (i) Mm‑Camk2g‑C2 
(Cat #522071‑C2) together with Mm‑Cldn5 (Cat #491611) and (ii) Mm‑Camk2d‑O1 (Cat #508941) 
together with Mm‑Cldn5‑C2 (Cat #491611‑C2). Slides were lightly counterstained with Gill’s hematox‑
ylin solution and mounted in VectaMountTM (Vector Laboratories Inc.). Images were acquired using 
a Nikon E400 microscope with ×40 or ×60 air objectives. Camk2g and Camk2d dot quantification (×60 
magnification) in claudin‑5 (Cldn5)‑positive vascular endothelial cells, the retinal GCL, INL, and ONL 
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was performed using ImageJ (65). Five images were obtained per slide from each mouse, where each 
slide contained 2–3 retinal sections. For each image, dots were quantified in 3 randomly selected regions 
of  interest per retinal region. Data are summarized as the average number of  dots per mm2.
CNV model. CNV lesions were created as previously described (75). In brief, WT and gene‑KO mice 
(6 months old) were anesthetized, and rupture of  Bruch’s membrane‑choroid was achieved by laser pho‑
tocoagulation (Haag Streit BM 900 Slit Lamp and Argon laser) using burns of  50 μm spot size (0.05‑sec‑
ond duration, 250 mW) approximately 2 disc diameters away from the optic disc. Animals were eutha‑
nized 7 days after laser treatment to quantify CNV lesions by multiphoton microscopy.
CNV lesion assessment. Enucleated eyes were fixed in 4% PFA. CNV lesions on retinal‑choroidal flatmounts 
were stained for biotin‑labeled isolectin B4 (1:50; MilliporeSigma) and Alexa Fluor Streptavidin 568 (1:500; 
Invitrogen) and imaged using an upright Leica TCS SP8 multiphoton microscope (HC PL Fluotar 20×/0.50 
dry lens; Leica Microsystems). Isolectin stained lesions were excited at a wavelength of 830 nm using a Mai 
Tai DeepSee laser (Spectra Physics) and fluorescence captured using a nondescanned detector. Serial Z‑stacks 
were taken up to a depth of 300 μm at 1.5‑μm intervals, allowing images to be collected spanning the full 
thickness of the CNV lesions. Images were acquired and volume rendered for presentation using Leica LAS‑X 
software. For quantification, images were imported into IMARIS Bitplane 8.4.2 (Bitplane AG), and the total 
volume of the CNV lesion and total volume of the burn were measured. Data are presented, and were ana‑
lyzed, as the lesion volume expressed as a percentage of the total burn volume.
Gross retinal morphology and vascular network analysis. To assess gross retinal morphology in WT and 
gene‑KO mice (11 months old), eyes were enucleated, prefixed with 10% formalin for 10–30 minutes, and 
either placed in 10% formalin overnight or dissected to remove the front half  of  the eyeball, followed by 
overnight incubation in 10 % formalin. Eyes were then dehydrated and saturated with paraffin (Leica 
TP1020 tissue processor) and embedded in paraffin blocks using a Leica Arcadia system. Blocks were cut 
at 5‑μm thickness on a microtome (Leica RM2235), floated onto slides, and stained using a Bio‑Optica 
automated slide stainer. H&E‑stained slides were imaged on a Leica DMi8 microscope.
Vascular network analysis was performed using isolectin B4–stained retinal flatmounts from adult WT 
and gene‑KO mice (3–6 months old). Retinas were isolated and the vasculature fluorescently stained with 
biotin‑labeled isolectin B4 (1:50; MilliporeSigma) and Alexa Fluor Streptavidin 568 (1:500; Invitrogen). 
Flat‑mounted retinas were imaged using a Leica SP8 resonance scanning confocal microscope (HC PL FLU‑
OTAR 10x 0.3 dry lens; Leica Microsystems). The tile and auto‑stitch functions of the microscope were used 
to produce an image of the entire superficial vascular plexus of the retina. Total vessel length, branching index 
(number of junctions per mm2), and lacunarity were quantified using AngioTool software (76).
Statistics. Most statistical analyses were carried out on the raw data using Prism V5.03 (GraphPad Soft‑
ware). Percentage data obtained from the OIR and CNV experiments were arcsine transformed prior to 
analysis. All datasets were tested to verify that they fulfilled the requirements for a normal distribution 
(D’Agostino and Pearson omnibus normality test). One‑way ANOVA was used followed by Bonferonni 
post‑hoc tests to compare differences among multiple groups. Two‑tailed Students t test was used to com‑
pare data between two groups when appropriate. Cell viability data were analyzed using the χ2 test. Data 
from the phospho‑kinase arrays were analyzed by ANOVA using the web‑based 1‑way NIA array analysis 
tool (77). This enabled significant changes in the phosphorylation status of  individual kinases across treat‑
ment groups to be detected, while correcting for multiple comparisons using the FDR method of  Benjamini 
and Hochberg (78). In all experiments, a P value of  0.05 was considered statistically significant.
Study approval. All animal procedures were approved by Queen’s University of  Belfast Animal Wel‑
fare and Ethical Review Body (AWERB) and authorized under the UK Animals (Scientific Procedures) 
Act 1986. Animal use conformed to the standards in the Association for Research in Vision and Oph‑
thalmology (ARVO) Statement for the Use of  Animals in Ophthalmic and Vision Research and with 
European Directive 210/63/EU.
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